Moreover, whereas we did not observe a difference in lifetime breast cancer risk between patients with tier 1 vs tier 2 PTEN variants, those with tier 2 PTEN variants had lower lifetime risks of all other component cancer types, although the risks of thyroid, breast, endometrial, and kidney cancers remain significantly higher than risks in the general population. This evidence concerns the gene PTEN and breast carcinoma.